Jim Cramer Praises Eli Lilly’s Performance
Key takeaways
- Cramer noted that the company is “creating a lot of jobs,” as he said:
- Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly.
- When David Ricks, CEO of Lilly, came on CNBC this morning, he said that things were pretty strong.
Jim Cramer Praises Eli Lilly’s Performance Syeda Seirut Javed Sun, May 3, 2026 at 10:51 PM GMT+7 2 min read LLY NVO Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said:
Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. Lilly astounded people today by reporting a fantastic quarter with encouraging prescription data for the new pill form of the GLP-1 drug, Foundayo. There was some worry that this drug had gotten off to a slow start. A lot of rumors going around Wall Street that it was a bummer. Novo Nordisk was said to be way ahead of Lilly because it got approved earlier. As is often the case, the Wall Street gas-bags got it wrong.
When David Ricks, CEO of Lilly, came on CNBC this morning, he said that things were pretty strong. Strong demand for the pill, more than 20,000 people now taking it, even as the company had only just started marketing it and building the brand. That’s good news for my Charitable Trust. We’ve been telling people to stick with Lilly no matter what. Just too much good going on there. I think that Eli Lilly’s gain today is sensational, and this company is creating a lot of jobs… But it is, alas, a healthcare company, and healthcare companies are not indicators of good times. When it comes to the stock market, drug companies, they’re bad leaders.